{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:03:13Z","timestamp":1790892193061,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10067-023-06647-z","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T01:03:50Z","timestamp":1685667830000},"page":"2469-2475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3581-6090","authenticated-orcid":false,"given":"David T.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancee V.","family":"Waterbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"6647_CR1","first-page":"831","volume":"90","author":"BL Hainer","year":"2014","unstructured":"Hainer BL, Matheson E, Wilkes RT (2014) Diagnosis, treatment, and prevention of gout. Am Fam Physician 90:831\u2013836","journal-title":"Am Fam Physician"},{"key":"6647_CR2","doi-asserted-by":"publisher","first-page":"e27817","DOI":"10.1371\/journal.pone.0027817","volume":"6","author":"H Ito","year":"2011","unstructured":"Ito H, Abe M, Mifune M et al (2011) Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One 6:e27817. https:\/\/doi.org\/10.1371\/journal.pone.0027817","journal-title":"PLoS One"},{"key":"6647_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E (2020) Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 16:380\u2013390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1","journal-title":"Nat Rev Rheumatol"},{"key":"6647_CR4","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/acr.24339","volume":"73","author":"LN Helget","year":"2021","unstructured":"Helget LN, England BR, Roul P et al (2021) Incidence, prevalence, and burden of gout in the Veterans Health Administration. Arthritis Care Res (Hoboken) 73:1363\u20131371. https:\/\/doi.org\/10.1002\/acr.24339","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6647_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"JA Singh","year":"2011","unstructured":"Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 23:192\u2013202. https:\/\/doi.org\/10.1097\/BOR.0b013e3283438e13","journal-title":"Curr Opin Rheumatol"},{"key":"6647_CR6","doi-asserted-by":"publisher","first-page":"E135","DOI":"10.5888\/pcd14.170230","volume":"14","author":"Y Liu","year":"2017","unstructured":"Liu Y, Sayam S, Shao X et al (2017) Prevalence of and trends in diabetes among veterans, United States, 2005-2014. Prev Chronic Dis 14:E135Published 2017 Dec 14. https:\/\/doi.org\/10.5888\/pcd14.170230","journal-title":"Prev Chronic Dis"},{"key":"6647_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","volume":"172","author":"M Fralick","year":"2020","unstructured":"Fralick M, Chen SK, Patorno E, Kim SC (2020) Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study. Ann Intern Med 172:186\u2013194. https:\/\/doi.org\/10.7326\/M19-2610","journal-title":"Ann Intern Med"},{"key":"6647_CR8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pds.5252","volume":"30","author":"LC Lund","year":"2021","unstructured":"Lund LC, H\u00f8jlund M, Henriksen DP, Hallas J, Kristensen KB (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf 30:1391\u20131395. https:\/\/doi.org\/10.1002\/pds.5252","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"6647_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.13101","volume":"20","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Xu L, Tian D et al (2018) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(2):458\u2013462. https:\/\/doi.org\/10.1111\/dom.13101","journal-title":"Diabetes Obes Metab"},{"key":"6647_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372\u2013382. https:\/\/doi.org\/10.1111\/dom.12054","journal-title":"Diabetes Obes Metab"},{"key":"6647_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/dom.12149","volume":"15","author":"N Inagaki","year":"2013","unstructured":"Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H (2013) Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15:1136\u20131145. https:\/\/doi.org\/10.1111\/dom.12149","journal-title":"Diabetes Obes Metab"},{"key":"6647_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"6647_CR13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"6647_CR14","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528\u20132536. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"6647_CR15","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","volume":"139","author":"GA Figtree","year":"2019","unstructured":"Figtree GA, R\u00e5dholm K, Barrett TD et al (2019) Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation 139:2591\u20132593. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040057","journal-title":"Circulation"},{"key":"6647_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"6647_CR17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation 138:458\u2013468. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034222","journal-title":"Circulation"},{"key":"6647_CR18","doi-asserted-by":"publisher","first-page":"e2135353","DOI":"10.1001\/jamanetworkopen.2021.35353","volume":"4","author":"MC Chung","year":"2021","unstructured":"Chung MC, Hung PH, Hsiao PJ et al (2021) Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open 4:e2135353. Published 2021 Nov 1. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353","journal-title":"JAMA Netw Open"},{"key":"6647_CR19","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve SV, Zhou Z et al (2019) The effects of canagliflozin on gout in type 2 diabetes: a posthoc analysis of the CANVAS Program. Lancet Rheumatol 1:e220\u2013e228. https:\/\/doi.org\/10.1016\/S2665-9913(19)30078-5","journal-title":"Lancet Rheumatol"},{"key":"6647_CR20","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","volume":"308","author":"Y Lytvyn","year":"2015","unstructured":"Lytvyn Y, \u0160krti\u0107 M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 308:F77\u2013F83. https:\/\/doi.org\/10.1152\/ajprenal.00555.2014","journal-title":"Am J Physiol Renal Physiol."},{"key":"6647_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pds.3780","volume":"24","author":"N Pratt","year":"2015","unstructured":"Pratt N, Chan EW, Choi NK et al (2015) Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries. Pharmacoepidemiol Drug Saf 24:858\u2013864. https:\/\/doi.org\/10.1002\/pds.3780","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6647_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1097\/JU.0000000000001079","volume":"204","author":"TE Dyson","year":"2020","unstructured":"Dyson TE, Cantrell MA, Lund BC (2020) Lack of association between 5\u03b1-reductase inhibitors and depression. J Urol 204:793\u2013798. https:\/\/doi.org\/10.1097\/JU.0000000000001079","journal-title":"J Urol"},{"key":"6647_CR23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/rheumatology\/kex363","volume":"57","author":"SW Niu","year":"2018","unstructured":"Niu SW, Chang KT, Lin HY et al (2018) Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology (Oxford) 57:92\u201399. https:\/\/doi.org\/10.1093\/rheumatology\/kex363","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06647-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06647-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T03:34:03Z","timestamp":1697081643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06647-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6647"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06647-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None of these sponsors had any role in the study design, methods, analyses, and interpretation, or in preparation of the manuscript and the decision to submit it for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}